U.S. Preclinical Cro Market Size & Outlook, 2023-2030
U.S. preclinical cro market, 2018-2030 (US$M)
Related Markets
U.S. preclinical cro market highlights
- The U.S. preclinical cro market generated a revenue of USD 2,551.8 million in 2023 and is expected to reach USD 4,228.1 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 2,551.8 million |
| Market revenue in 2030 | USD 4,228.1 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, U.S. accounted for 44.7% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 4,228.1 million by 2030.
Toxicology testing was the largest segment with a revenue share of 26.15% in 2023. Horizon Databook has segmented the U.S. preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounts for the highest share in the global preclinical trial outsourcing market as a large number of pharmaceutical and life sciences companies are present in this region. CROs in the country possess various capabilities such as genotoxicity and immunotoxicity testing services, which are majorly carried out in the U.S. Along with this, rapid growth in emerging areas of medicine such as personalized medicines, orphan drugs, and biosimilar is expected to propel growth of the preclinical trial outsourcing market in the U.S.
A significant proportion of R&D expenditure by pharmaceutical and life sciences companies are allotted to preclinical trials. Adherence to safety protocols is ensured during the preclinical trials phase before undertaking further stages of drug development.
In addition, failure rate of preclinical trials is significantly lower than failures in further stages. Significant investments were made for preclinical studies by the pharmaceutical companies in recent years.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. preclinical cro market size, by service, 2018-2030 (US$M)
U.S. Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
